Search results for "Injection"

showing 10 items of 920 documents

Intratympanic Dexamethasone and Hyaluronic Acid in Patients with Low-Frequency and Ménière's-Associated Sudden Sensorineural Hearing Loss

2005

Steroids are widely used for the treatment of cochleovestibular disorders. Direct steroid application in the middle ear cavity, when combined with a round window membrane permeability-modulating substance, increases the level of the steroid reaching the target cells. We measured hearing in patients with idiopathic isolated low-frequency sensorineural hearing loss and in patients with sudden sensorineural hearing loss and a history of Ménière's disease. Contradictory reports about effectiveness of intratympanic steroid therapy on vertigo control and hearing improvement in patients with Ménière's disease exist in the literature.Eighteen patients with isolated low-frequency idiopathic sudden s…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing lossHearing Loss SensorineuralAnti-Inflammatory AgentsInjections IntralesionalAudiologyDexamethasoneAdjuvants ImmunologicVertigootorhinolaryngologic diseasesmedicineHumansProspective StudiesHyaluronic AcidProspective cohort studyMeniere DiseaseDexamethasoneRound windowbiologymedicine.diagnostic_testbusiness.industryAuditory ThresholdHearing Loss SuddenMiddle Agedbiology.organism_classificationmedicine.diseaseSensory SystemsTreatment Outcomemedicine.anatomical_structureOtorhinolaryngologyMiddle earAudiometry Pure-ToneFemaleSensorineural hearing lossNeurology (clinical)medicine.symptomAudiometrybusinessmedicine.drugOtology & Neurotology
researchProduct

Pharmacokinetics of atenolol in relation to renal function

1981

The plasma levels and urinary excretion of carteolol and its main metabolites 8-hydroxycarteolol and carteolol glucuronide were investigated in 6 healthy subjects and 9 patients with varying degrees of renal impairment following a single oral dose of 30 mg carteolol hydrochloride. In healthy subjects the half-life of carteolol was 7.1 h. 63% of the administered dose was recovered unchanged in urine, and in all 84% was excreted by the kidneys. The renal clearance of carteolol was 255 ml/min. In chronic renal failure (CRF) the terminal half-life was increased to a maximum of 41 h. Both the elimination rate constant and renal clearance were closely related to the creatinine clearance. In CRF t…

AdultMalemedicine.medical_specialtyUrologyAdministration OralRenal functionCarteolol HydrochloridePropanolamineschemistry.chemical_compoundPharmacokineticsElimination rate constantRenal DialysisInternal medicinemedicineHumansPharmacology (medical)CarteololAgedPharmacologyKidneyCreatinineMaintenance dosebusiness.industryGeneral MedicineMiddle AgedKineticsEndocrinologymedicine.anatomical_structureAtenololchemistryInjections IntravenousFemaleKidney DiseasesbusinessGlomerular Filtration Ratemedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

2011

To evaluate adalimumab therapy in refractory uveitis.Prospective case series.A total of 131 patients with refractory uveitis and intolerance or failure to respond to prednisone and at least 1 other systemic immunosuppressive drug participated.Patients received a 40 mg adalimumab subcutaneous injection every other week for 6 months. The associated immunosuppressants were tapered after administering 3 adalimumab injections (week 6).Degree of anterior and posterior chamber inflammation (Standardization of Uveitis Nomenclature Working Group criteria), immunosuppression load (as defined by Nussenblatt et al), visual acuity (logarithm of the minimal angle of resolution [logMAR]), and macular thic…

AdultMalemedicine.medical_specialtyVisual acuityAdolescentInjections SubcutaneousAnti-Inflammatory AgentsDrug ResistanceVisual AcuityArthritisAntibodies Monoclonal HumanizedUveitisRefractoryPrednisoneInternal medicineAdalimumabMedicineHumansMacula LuteaProspective StudiesPars PlanitisProspective cohort studyChildGlucocorticoidsbusiness.industryTumor Necrosis Factor-alphaAdalimumabOff-Label Usemedicine.diseaseSurgeryOphthalmologyMethotrexateTreatment OutcomeChild PreschoolCyclosporineFemalemedicine.symptombusinessUveitisTomography Optical Coherencemedicine.drugOphthalmology
researchProduct

Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months.

2009

Purpose To report the anatomic and functional outcomes of intravitreal clindamycin and dexamethasone for the treatment of zone 1 toxoplasmic retinochoroiditis (TRC). Patients had 1 or more of the following indications for local therapy: intolerance to oral medication, contraindication to oral medication because of pregnancy, lack of response despite oral antimicrobial treatment, or treatment with concomitant oral and local therapy to avoid or limit foveal or optic disc involvement. Design Noncomparative, retrospective, multicentric interventional case series. Participants We reviewed the medical records of 12 consecutive patients (eyes) with posterior pole (zone 1) TRC who were treated week…

AdultMalemedicine.medical_specialtyVisual acuitygenetic structuresEye diseasePosterior poleAntiprotozoal AgentsVisual AcuityDexamethasoneInjectionsYoung AdultPregnancymedicineHumansFluorescein AngiographyToxoplasmosis OcularContraindicationGlucocorticoidsAntibacterial agentRetrospective Studiesmedicine.diagnostic_testbusiness.industryClindamycinDiabetic retinopathyMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesSurgeryVitreous BodyOphthalmologyTreatment OutcomeChorioretinitisPregnancy Complications ParasiticDrug Therapy CombinationFemalesense organsmedicine.symptombusinessTomography Optical CoherenceRetinopathyFollow-Up StudiesOphthalmology
researchProduct

ACUTE VISION LOSS AS THE ONLY SIGN OF LEUKEMIA RELAPSE.

2016

Purpose To report a case of unilateral exudative retinal detachment as the sole presentation of relapsing B-type lymphoblastic leukemia in a 35-year-old man after 3 years of remission. Methods Case report. Results A 35-year-old man in complete remission of high-risk type B acute lymphoblastic leukemia (ALL-B) presented with acute vision loss in his left eye. Exudative retinal detachment was diagnosed at initial evaluation. Hematological and ocular studies were performed. Although there was no evidence of blood, cerebrospinal fluid, or bone marrow disease relapse, transvitreal retinochoroidal cytology identified the infiltration of lymphoblastic leukemic B cells with t(12:21) translocation a…

AdultMalemedicine.medical_specialtyVisual acuitymedicine.medical_treatmentBiopsyVisual AcuityVitrectomyAntineoplastic AgentsEndotamponadeBlindnessGastroenterology03 medical and health sciences0302 clinical medicineCerebrospinal fluidRecurrencehemic and lymphatic diseasesInternal medicineCytologyPrecursor B-Cell Lymphoblastic Leukemia-LymphomaVitrectomyBiopsymedicineHumansSilicone OilsB Acute Lymphoblastic Leukemiamedicine.diagnostic_testbusiness.industryRetinal DetachmentMagnetic resonance imagingGeneral MedicineExudative retinal detachmentFlow CytometryMagnetic Resonance ImagingOphthalmology030220 oncology & carcinogenesisAcute Disease030221 ophthalmology & optometrymedicine.symptomInjections IntraocularbusinessRetinal casesbrief reports
researchProduct

Timing of cell division in human cleavage-stage embryos is linked with blastocyst formation and quality

2012

Noninvasive markers of embryo quality are being sought to improve IVF success. The present study aimed to discover possible associations between embryo division kinetics in the cleavage stage, the subsequent ability of human embryos to reach the blastocyst stage and the resulting blastocyst morphology. A retrospective cohort study analysed 834 embryos from 165 oocyte donation couples using a time-lapse monitoring system that allowed the recording of the exact timings for key events related to embryo development. Timing parameters were categorized into four quartiles. The probability of an embryo developing to a blastocyst was linked to a strict chronology of development. To further evaluate…

AdultMalemedicine.medical_specialtyanimal structuresAdolescentCell divisionBiologyModels BiologicalTime-Lapse ImagingCohort StudiesAndrologyYoung AdultEmbryo cryopreservationmedicineHumansSperm Injections IntracytoplasmicBlastocystEctogenesisreproductive and urinary physiologyRetrospective StudiesGynecologyOocyte DonationEmbryogenesisObstetrics and GynecologyEmbryoEmbryo TransferEmbryo MammalianEmbryo transferKineticsBlastocystmedicine.anatomical_structureReproductive Medicineembryonic structuresEctogenesisFemaleInfertility FemaleBiomarkersCell DivisionEmbryo qualityDevelopmental BiologyReproductive BioMedicine Online
researchProduct

Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study

2019

Background: Graves' disease is one of the most common autoimmune conditions, but treatment remains imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves' hyperthyroidism. Methods: Twelve participants (11 female) with previously untreated mild to moderate Graves' hyperthyroidism were enrolled in a Phase I open label trial to receive 10 doses of ATX-GD-59 administered intradermally over an 18-week period. Adverse events, tolerability, changes in serum free thyroid hormones, and TSHR autoantibodies were measured. Results: Ten subjects received all 10 doses of ATX-GD-59,…

AdultMalemedicine.medical_specialtyendocrine systemendocrine system diseasesInjections Intradermalthyroid stimulating hormone receptorEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGraves' diseasedesensitization030209 endocrinology & metabolismDiseaseImmunology Autoimmunity and Graves’ OphthalmopathyimmunomodulationThyrotropin receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineHumansAdverse effectDesensitization (medicine)business.industryAutoantibodypeptide immunotherapyReceptors ThyrotropinImmunotherapyMiddle Agedmedicine.diseaseGraves' diseaseGraves Disease3. Good healthInjection Site ReactionThyroxineEndocrinologyTreatment OutcomeTolerabilityDesensitization Immunologic030220 oncology & carcinogenesisTriiodothyronineFemaleautoimmune thyroid diseasebusinessPeptidesImmunoglobulins Thyroid-StimulatingThyroid
researchProduct

Patient-Reported Nonadherence with Glaucoma Therapy

2019

Abstract Purpose: Effective glaucoma therapy relies to a great extent on the patients' ability to regularly self-administer eye drops. This study aimed to assess self-reported nonadherence and to identify potential barriers to adherence in glaucoma patients. Methods: Participants completed a 16-item questionnaire, designed to examine nonadherence rate and assess the therapy experience. Inclusion criteria stipulated treatment duration of at least 1 year. Nonadherence was defined as missing ≥5% of the prescribed pressure-lowering eye drops doses. Results: In total, 201 glaucoma patients aged 24–88 years were included. Mean treatment duration was 9.4 years. Nonadherence was reported by 30.3% o…

AdultMalemedicine.medical_specialtygenetic structuresGlaucomaoutcomesYoung AdultGermanySurveys and QuestionnairesmedicineHumansPharmacology (medical)adherencePatient Reported Outcome MeasuresIntensive care medicineAntihypertensive AgentsAgedPharmacologyAged 80 and overnonadherencebusiness.industryPreservatives PharmaceuticalGlaucomaOriginal ArticlesMiddle Agedmedicine.diseaseeye diseasesOphthalmologyside effectsPatient ComplianceFemalesense organspreservativesInjections IntraocularOphthalmic SolutionsbusinessJournal of Ocular Pharmacology and Therapeutics
researchProduct

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

2018

Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. Methods: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA–SLEDAI] score ≥8) were randomized (2:1) to receive weekl…

AdultMalemedicine.medical_specialtymedicine.drug_classInjections SubcutaneousPopulationImmunologyPlaceboAntibodies Monoclonal HumanizedGastroenterologySystemic Lupus ErythematosusSeverity of Illness Index03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineeducationAdverse effectskin and connective tissue diseases030203 arthritis & rheumatologyeducation.field_of_studyLupus erythematosusIntention-to-treat analysisbusiness.industryComplement C3DNAmedicine.diseaseBelimumabRheumatologyIntention to Treat AnalysisTreatment OutcomeAntibodies AntinuclearImmunology and Allergy; Rheumatology; ImmunologyCorticosteroidOriginal ArticleFemalebusinessmedicine.drug
researchProduct

Effect of intravenous application of esomeprazole 40???mg versus pantoprazole 40???mg on 24-hour intragastric pH in healthy adults

2007

BACKGROUND: It has been demonstrated that therapy with proton pump inhibitors reduces recurrence of bleeding following initial endoscopic treatment of bleeding peptic ulcers. AIM: This study compared the effects of esomeprazole 40 mg and pantoprazole 40 mg on intragastric acid control. Both substances were administered intravenously as 15-min infusion and as bolus injection. METHODS: Healthy men and women volunteers were enrolled in this single-center, open, randomized, three-way crossover study. After administration of esomeprazole 40 mg and pantoprazole 40 mg intravenously as 15-min infusion, and pantoprazole 40 mg intravenously as bolus injection, continuous 24-h intragastric pH monitori…

AdultMalemedicine.medical_specialtymedicine.drug_classPepticProton-pump inhibitorPharmacologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesHelicobacter InfectionsEsomeprazoleGastric AcidInternal medicineHumansMedicineEsomeprazole SodiumInfusions IntravenousPantoprazoleMonitoring PhysiologicPantoprazoleCross-Over StudiesHelicobacter pyloriHepatologybusiness.industryStomachGastroenterologyEsomeprazoleGastric Acidity DeterminationHydrogen-Ion ConcentrationMiddle AgedAnti-Ulcer AgentsCrossover studymedicine.anatomical_structureInjections IntravenousBody ConstitutionGastric acidFemalebusinessmedicine.drugEuropean Journal of Gastroenterology &amp; Hepatology
researchProduct